Navigation Links
Trovagene Announces Broadening Network of Commercial Distributors
Date:1/12/2017

SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) technologies, today announced that it has signed agreements with seven strategic partners across Europe and the Middle East for commercialization of the Trovera™ liquid biopsy tests.  This milestone marks the first wave of international distribution agreements for Trovagene's CLIA based liquid biopsy tests for urine and blood samples.

The initial partners will introduce Trovagene's liquid biopsy tests to physicians, laboratories and cancer centers in key regional markets.  In addition, these partners will have early access to Trovagene's research use only liquid biopsy kits and systems to distribute to clinical research facilities in Europe, Middle East, Africa and Asia.

These strategic partners include Alliance Global (AGBL) for the Middle East, Africa, Central and South Asia, Instituto Diagnostico Varelli (Italy), Progenetics (Israel), Amplitech (France, Belgium and Switzerland), NM Genomix (Bulgaria and East Europe), Diagnostica Longwood (Spain and Portugal), and Sorgente Genetica (Italy). 

"We are excited to announce that physicians and patients in these international markets now have access to our industry leading laboratory developed tests for EGFR, KRAS, and BRAF mutations in urine and blood," said Bill Welch, Chief Executive Officer of Trovagene.

Trovagene is pleased to partner with these premier life science and diagnostic organizations.  In addition to the well-established clinical next-generation sequencing and research business channels they have created in their regions, this network also provides the infrastructure for scientific education, training and support of new technologies and future product introductions.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in an effort to enable itself, and others through the distribution of research use kits and systems, to detect and monitor ctDNA in urine and blood. The Company's technology allows for detection and quantitation of oncogene mutations in cancer patients for improved disease management. Trovagene's PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property, including multiple issued patents and pending patent applications globally. For more information, please visit http://www.trovagene.com/.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; our ability to develop tests, kits and systems and the success of those products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technologies or products will be utilized by oncologists or prove to be commercially successful, or that Trovagene's strategy to design its PCM platform to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2015 and other periodic reports filed with the Securities and Exchange Commission.

Trovagene Contacts:


Beth Anderson

VP, Finance & AdministrationVicki Kelemen

Sr. Director, Marketing Communications858-952-7593858-952-7652ir@trovagene.com vkelemen@trovagene.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-announces-broadening-network-of-commercial-distributors-300390107.html


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform
2. Clinical Data Featuring Trovagenes Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences
3. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
4. SomaLogic announces that it has joined the iCarbonX Digital Life Alliance
5. Cloudtag Announces Onitor Track, a Weight Loss Program and Wearable for the Age of Data, at the 2017 Consumer Electronics Show
6. AIC Announces Release of New White Paper on Using NVMe Storage Servers to Build High-performance, Scale-out Storage for HPC Applications
7. Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
8. Securus Announces Third DOC Facility to Approve/Accept Its Managed Access Systems (MAS) Technology
9. The Weather Company Announces Watson Ads, To Humanize The Ad Experience for Consumers with Industry-First Capability
10. Neurotechnology Announces MegaMatcher Automated Biometric Identification System (ABIS)
11. Crossmatch Announces Latest DigitalPersona Altus Authentication Solution Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft System ... over the next decade to reach approximately $14.21 billion by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):
(Date:6/19/2017)... ... June 19, 2017 , ... ... service activities supporting EDETEK’s products including training, implementation, support, and client process and ... new role. He has previously held leadership roles for service providers and top-tier ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy honey ... and tissues by delivering pollen and nectar containing nutrients necessary for growth and survival. ... healthy. , Many recent indicators point to a decline in honey bee health. Sick ...
(Date:6/16/2017)... ... June 16, 2017 , ... CTNext , Connecticut’s ... Awards (EIA), held at The LOFT at Chelsea Piers in Stamford. , Nine finalists, ... a panel of judges for an opportunity to secure $10,000 awards to help support ...
(Date:6/15/2017)... ... June 15, 2017 , ... The newest exhibition at the ... creative experimentation and interdisciplinary collaboration. Feature Creep, a solo exhibition by Maximillian Lawrence, ... will be held at EKG, located at 3600 Market Street in Philadelphia, on ...
Breaking Biology Technology: